Comparison of Low Dose Recombinant Factor VIIa and 4-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Cardiac Surgery.

Autor: Caldwell, Lauren, Bhakta, Rima, Naik, Neha, Knowles, B.D., Parker, Jessica, Van Berkel Patel, Megan
Předmět:
Zdroj: Journal of Pharmacy Practice; Oct2024, Vol. 37 Issue 5, p1149-1156, 8p
Abstrakt: Background: Recombinant factor VIIa (rFVIIa) and prothrombin concentrate complex (PCC) are used for uncontrolled bleeding in cardiac surgery (CS), however, there are limited direct comparisons of these agents. Objective: To evaluate the efficacy and safety of rFVIIa and PCC in CS related bleeding. Methods: This retrospective study included adult CS patients who received either low dose rFVIIa (< 30 mcg/kg) or 4-factor PCC. The primary outcome was transfusion requirements of packed red blood cells (pRBC) within 6 hours of factor administration. Secondary efficacy outcomes included transfusion requirements 0-18 hours, doses of additional factor product, thrombotic events, and acute kidney injury (AKI). Results: A total of 179 patients were included (n = 78 rFVIIa; n = 101 PCC). Of patients who received blood products, there was no difference in the requirement of pRBCs within 6 hours (73.8 vs 68.9%, P =.5359) or in the median amount of pRBC transfused (500 mL vs 640 mL, P =.0723) in the rFVIIa and PCC groups respectively. Patients in the PCC group were more likely to require additional factor products (24.4% vs 47.5%, P =.0015), develop AKI (12.8% vs 25.7%, P =.0325), have longer ICU lengths of stay [2 (IQR 1-5) vs 4 (IQR 2-6), P =.0487] and greater in-hospital mortality (2.6% vs 10.9%, P =.033). There was no difference in thrombotic events. Conclusion: Although, there was no difference in pRBC transfusion requirements between PCC and rFVIIa, more patients in the PCC group required additional factor products and had increased adverse effects. Further comparisons of PCC and rFVIIa are warranted. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index